CIK 1796461
Long positions in SEC Section 13(f) securities (US-listed stocks, ADRs and ETFs), largest first · Δ vs 2021-Q1. A lagged quarterly snapshot (filed ≤45 days after quarter-end); excludes shorts, options, cash, and shares listed only on non-US exchanges — foreign companies held via a US listing or ADR (e.g. Alibaba, TSMC) ARE included.
As filed = each book applied at its quarter-end (what the reported book did) · As copyable = applied at its statutory 45-day filing deadline (what a 13F follower could have earned).
Computing…
Hypothetical modeled performance constructed with hindsight — not actual results, and not indicative of future results. See the Disclaimer.
| Industry group | Weight | Names |
|---|---|---|
| Pharmaceuticals & Biotechnology | 53.85% | 11 |
| Unclassified | 39.45% | 10 |
| Professional Services | 6.70% | 1 |
| # | Ticker | Name | Sector | Weight |
|---|---|---|---|---|
| 1 | BCRX | BIOCRYST PHARMACEUTICALS INC | Health Care | 13.71% |
| 2 | NTLA | Intellia Therapeutics, Inc. | Health Care | 10.33% |
| 3 | EPIZYME INC. | Unclassified | 6.97% | |
| 4 | ESSA PHARMA INC | Unclassified | 6.80% | |
| 5 | NEO | NEOGENOMICS INC | Industrials | 6.70% |
| 6 | MEI PHARMA INC | Unclassified | 6.66% | |
| 7 | CRNX | Crinetics Pharmaceuticals, Inc. | Health Care | 5.57% |
| 8 | CYTK | CYTOKINETICS INC | Health Care | 4.85% |
| 9 | AMICUS THERAPEUTICS INC | Unclassified | 4.83% | |
| 10 | HRMY | Harmony Biosciences Holdings, Inc. | Health Care | 4.25% |
12/22 names classified · sector 60.5% of weight · industry 60.5% · mkt cap 60.5%; unclassified names shown, never dropped.
Sector is classified on each name's CURRENT fundamentals, not point-in-time — apparent sector drift can reflect the market re-rating a holding, not a manager trade. 13F is a lagged quarterly snapshot of long positions in US-listed securities only — foreign companies held via a US listing or ADR ARE included, but shares listed only on non-US exchanges (plus shorts, options and cash) are not. Latest quarter: 60.5% of the book is sector-classified (unclassified names shown, never dropped).
Only 18% of book weight classified — the grid is NOT representative of the whole book.
Classified: 18.0% of book weight (2/13 names) · unclassified 82.0%: , NTLA, NEO, CRNX, CYTK, MIRM, ADCT, VSTM, GERN, RVMD +1 more. Size: cap 70/20/10 bands; style: value/growth composite on our own metrics — not Morningstar's model.
No contribution data for this period.
| # | Security | Shares | Value | Weight | Δ QoQ |
|---|---|---|---|---|---|
| 1 | BCRXBIOCRYST PHARMACEUTICALS INC | 864,916 | $14M | 13.7% | HOLD |
| 2 | NTLAINTELLIA THERAPEUTICS INC | 63,634 | $10M | 10.3% | HOLD |
| 3 | EPIZYME INC. | 836,802 | $7M | 7.0% | ADD 48% |
| 4 | ESSA PHARMA INC | 237,442 | $7M | 6.8% | HOLD |
| 5 | NEONEOGENOMICS INC | 147,921 | $7M | 6.7% | HOLD |
| 6 | MEI PHARMA INC | 2,331,313 | $7M | 6.7% | HOLD |
| 7 | CRNXCRINETICS PHARMACEUTICALS IN | 294,620 | $6M | 5.6% | ADD 8% |
| 8 | CYTKCYTOKINETICS INC | 244,673 | $5M | 4.9% | HOLD |
| 9 | AMICUS THERAPEUTICS INC | 500,000 | $5M | 4.8% | NEW |
| 10 | HRMYHARMONY BIOSCIENCES HLDGS IN | 150,000 | $4M | 4.2% | HOLD |
| 11 | INOZYME PHARMA INC | 242,517 | $4M | 4.1% | ADD 43% |
| 12 | Y-MABS THERAPEUTICS INC COM | 114,454 | $4M | 3.9% | HOLD |
| 13 | MIRMMIRUM PHARMACEUTICALS INC | 205,866 | $4M | 3.6% | HOLD |
| 14 | ADCTADC THERAPEUTICS SA | 124,875 | $3M | 3.0% | HOLD |
| 15 | VSTMVERASTEM INC | 705,585 | $3M | 2.9% | NEW |
| 16 | MERUS N V | 130,683 | $3M | 2.8% | HOLD |
| 17 | GERNGERON CORP | 1,912,673 | $3M | 2.7% | HOLD |
| 18 | AVROBIO INC | 244,920 | $2M | 2.2% | HOLD |
| 19 | RVMDREVOLUTION MEDICINES INC | 50,000 | $2M | 1.6% | NEW |
| 20 | BDTXBLACK DIAMOND THERAPEUTICS I | 110,447 | $1M | 1.3% | HOLD |
| 21 | G1 THERAPEUTICS INC | 47,708 | $1M | 1.0% | TRIM −59% |
| 22 | TURNING POINT THERAPEUTICS INC. | 2,164 | $169,000 | 0.2% | TRIM −97% |
Where this firm's principals came from and which firms its alumni went on to found.
